Gabapentin and Tizanidine for Insomnia in Chronic Pain

Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Jun 10, 2020

Keywords

ClinConnect Summary

Chronic pain and insomnia are highly prevalent conditions affecting 10-25% and 6-10% of the general population, respectively. Importantly, these two conditions frequently co-occur, with 50-80% of chronic pain patients reporting sleep disturbances. Identifying medication that alleviates pain and insomnia simultaneously may help reduce risks associated with polypharmacy, including drug-drug interactions.

In this double-blind, placebo-controlled, randomized, crossover trial, gabapentin and tizanidine, two drugs which are respectively commonly used to treat neuropathic and musculoskeletal pain...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • BMI ≤ 35
• • Any ethnicity
• • Must be able to communicate in English
• • Must have access to email and be able to respond to REDCap questionnaires in English
• • Has a chronic pain condition (≥ 3 months of pain)
• • Reports sleep disturbance and scores ≥ 6 on AIS questionnaire
• • Ability to provide informed consent
• Exclusion Criteria:
• • Pregnancy
• • Breastfeeding
• • Has diagnosis of chronic kidney disease
• • Has known QT prolongation \>500 msec on prior EKG
• • Inability to complete daily questionnaires
• • Allergy to, or intolerance of, any of tizanidine or gabapentin
• • Shift workers
• • Anticipated travel across multiple time zones (jetlag) during the duration of the trial
• • Circadian misalignment
• • Prior syncope experience and/or fear of blood/needles (if a blood draw is required)

Trial Officials